Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Rhea-AI Summary
Novo Nordisk (NYSE:NVO) reported transactions in its shares by board members, executives and associated persons in line with Article 19 of the EU Market Abuse Regulation. Several directors and executive vice presidents, including the President and CEO and the CFO, had Novo Nordisk B shares vested under the Restricted Shares programme “Novo Nordisk 100th Anniversary Shares”. Each reported person received 74 shares (ISIN DK0062498333) at a reference price of DKK 294.30, corresponding to DKK 21,778.20 per individual vesting. The transactions were recorded on 5 August 2026 and took place outside a trading venue, and were notified to Novo Nordisk and disclosed as a company announcement.
Loading...
Loading translation...
Positive
- None.
Negative
- None.
News Market Reaction – NVO
+3.23%
14 alerts
+3.23%
Session close to close
-2.5%
Trough in 5 hr 19 min
$204.59B
Market Cap
1.1x
Rel. Volume
In the Aug 6 session, NVO gained 3.23%, reflecting a moderate positive market reaction. Argus tracked a trough of -2.5% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Bagsværd, Denmark, 6 August 2026 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | DÉSIRÈE JANTZEN ASGREEN | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 74 | |||||
| d) | Aggregated information
| 74 shares DKK 21,778.20 | ||||
| e) | Date of the transaction | 2026-08-05 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | ELISABETH DAHL CHRISTENSEN | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 74 | |||||
| d) | Aggregated information
| 74 shares DKK 21,778.20 | ||||
| e) | Date of the transaction | 2026-08-05 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | METTE BØJER JENSEN | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 74 | |||||
| d) | Aggregated information
| 74 shares DKK 21,778.20 | ||||
| e) | Date of the transaction | 2026-08-05 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | SEMSI KILIC MADSEN | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Member of the Board of Directors | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 74 | |||||
| d) | Aggregated information
| 74 shares DKK 21,778.20 | ||||
| e) | Date of the transaction | 2026-08-05 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | EMIL KONGSHØJ LARSEN | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, International Operations | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 74 | |||||
| d) | Aggregated information
| 74 shares DKK 21,778.20 | ||||
| e) | Date of the transaction | 2026-08-05 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | KARSTEN MUNK KNUDSEN | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, Chief Financial Officer (CFO) | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 74 | |||||
| d) | Aggregated information
| 74 shares DKK 21,778.20 | ||||
| e) | Date of the transaction | 2026-08-05 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | KASPER BØDKER MEJLVANG | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, Global Manufacturing & Supply | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 74 | |||||
| d) | Aggregated information
| 74 shares DKK 21,778.20 | ||||
| e) | Date of the transaction | 2026-08-05 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | MAZIAR MIKE DOUSTDAR | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | President and CEO | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 74 | |||||
| d) | Aggregated information
| 74 shares DKK 21,778.20 | ||||
| e) | Date of the transaction | 2026-08-05 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | MARTIN HOLST LANGE | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, R&D and Chief Scientific Officer (CSO) | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 74 | |||||
| d) | Aggregated information
| 74 shares DKK 21,778.20 | ||||
| e) | Date of the transaction | 2026-08-05 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | THILDE GYNTHE BØGEBJERG KRØYER | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, Enterprise IT & Quality | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 74 | |||||
| d) | Aggregated information
| 74 shares DKK 21,778.20 | ||||
| e) | Date of the transaction | 2026-08-05 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | TANIA SABROE | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Vice President, People, Organisation & Corporate Affairs | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument, type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Other transaction (vesting of shares in accordance with Restricted Shares programme – Novo Nordisk 100th Anniversary Shares) | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 74 | |||||
| d) | Aggregated information
| 74 shares DKK 21,778.20 | ||||
| e) | Date of the transaction | 2026-08-05 | ||||
| f) | Place of the transaction | Outside a trading venue | ||||
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.
Contacts for further information
| Media: | |
| Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
| Investors: | |
| Michael Novod +45 3075 6050 nvno@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com |
| Alex Bruce +45 3444 2613 axeu@novonordisk.com | Mads Berner Bruun +45 3075 2936 mbbz@novonordisk.com |
| Christoffer Togo Solgaard-Tullin +45 3079 1471 cftu@novonordisk.com | Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
| Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 49 / 2026
Attachment
FAQ
Why were the August 2026 Novo Nordisk (NVO) insider transactions reported as occurring outside a trading venue?
They were reported as occurring outside a trading venue because they involved vesting under a restricted share programme, not market trades. According to Novo Nordisk, the shares vested as part of the Novo Nordisk 100th Anniversary Shares programme and still required Article 19 disclosure.